Regarding the outcome of patients, we observed that advanced-stage HCC patients, with a median value of p-mTOR = 0, showed a median PFS of 5.3 months (95% CI 2.3–10.7) and a median OS of 13.9 months (95% CI 6.7–15.8), whereas those with a median value of p-mTOR > 0 had a median PFS of 1.8 months (95% CI 1.6–4.0) and a median OS of 6.1 months (95% CI 2.6–nr), (p = 0.055, p = 0.098, respectively) (Table 4). This evidence concerns the gene MTOR and hepatocellular carcinoma.